This page shows the latest lipegfilgrastim news and features for those working in and with pharma, biotech and healthcare.
There was better news for Teva's G-CSF portfolio however after it launched its long-acting G-CSF product Lonquex (lipegfilgrastim) on November 4 in Germany, the first EU market
Lonquex (lipegfilgrastim) has been approved to reduce the duration of neutropaenia (low white blood cell counts) and febrile neutropaenia in patients undergoing cytotoxic chemotherapy for cancer, and is given as a ... which like lipegfilgrastim is
Elsewhere, there were further recommendations for Teva's (Lonquex) lipegfilgrastim, which was recommended for the reduction in white blood cells of cancer patients on chemotherapy; Bavarian Nordic's smallpox vaccine Imnavex;
More from news
Approximately 1 fully matching, plus 2 partially matching documents found.
We are a patient engagement agency committed to making clinical study experiences human. By guiding organisations in making everything they...